We are the industry leader in research and development and sales of high performance cyclotron targets. Our cyclotron target system technology outperforms OEM systems by a factor of two, resulting in advantages to our retrofit customers of lower costs, improved scheduling and reliability, and increased sales of doses of radiopharmaceuticals.
We manufacture, install, and support four commercial product lines in a global marketplace. We are currently expanding product lines to enable a new business model using higher power cyclotrons to operate larger, centralized, more cost effective distribution centers for PET/CT radiopharmaceuticals.
Focus: Outstanding Targets with Unequaled Performance
Flexibility and Optimized Solutions
High performance cyclotron targets for PET, including conventional, thermosyphon, recirculating, and internal targets, optimized for each type of cyclotron
Education and Experience Resources
President & Vice President are both PhD engineers
History of targetry innovations from 1972 to present
Grant and Collaborator Support
NIH awards 2004 to 2008, pending 2010 award
Working with universities, large and small businesses
Intellectual Property Assets
Three US/EU patents issued, one pending
Performance, Reliability, Reputation
Single-target 18F yield equal to dual OEM targets, in routine use by satisfied customers starting 2008
Committed to Strategic Progress
Developing products for intense beam cyclotrons, for business model of large central distribution centers
Comprehensive Development Process for Commercial Targets
Advanced Computational Modeling Skills
- Subcontracted to the NC State Nuclear Engineering Graduate School
- Applying validated thermal hydraulic software to analysis of conceptual target geometries
Extensive Target Prototype Testing
Cyclotron experiments conducted at Duke University CS-30, the Wisconsin Medical Cyclotron PETtrace operated by Cyclomedical, and a Cyclone 30
Exceptional Commercial Retrofit Products
Targets sold for GE PETtrace, Siemens RDS-111/Eclipse, and Cyclopharma Laboratories 14 MeV (France)
Targets under development for: RDS-112, TR19, and Cyclone 30
Advanced Technology for the Future
R&D for future deployment includes bottom pressure, recirculating and internal beam targets, to transcend 3-4 kW limit of present retrofit target products. The goal is up to 25 kW, for example 1 mA of 25 MeV protons. New technology will be ready for commercialization as more advanced cyclotrons become available, to satisfy predicted increases in 18F radiopharmaceutical needs.